Guo Yue-Ping, Liu Yan, Li Jing-Bo, Huang Yun, Qi Han-Ping, Xie Jing, Cui Xiao-Guang, Yue Zi-Yong, Li Wen-Zhi
Department of Anesthesiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, P.R. China.
Cell Physiol Biochem. 2011;28(2):315-22. doi: 10.1159/000331747. Epub 2011 Aug 16.
Previous studies demonstrate that macrophages synthesis and release catecholamines, which regulate the immune responses in an autocrine manner. These responses are mediated in part by β-adrenoceptors expressed on macrophages. Some β-adrenoceptor antagonists are commonly used in clinical conditions. Here we investigated whether the chronic administration of β-adrenoceptor antagonists upregulate adrenergic system of alveolar macrophage and the potential mechanims.
Propranolol (30 mg/kg·d) or atenolol (5 mg/kg·d) was administered by gavage to rats for 4 weeks. Then alveolar macrophages were isolated and the expression of β(1) or β(2)-adrenoceptor was detected by flow cytometric analysis. Dopamine β-hydroxylase expression was assessed by Western blot assay and the concentrations of noradrenaline, IL-6, and TNF-α in cell supernatants were measured using ELISA after 2 h or 24 h exposure of alveolar macrophages to 100 ng/ml lipopolysaccharide (LPS).
Propranolol increased the mean fluorescence intensity (MFI) of β(1), β(2)-adrenoceptor and the frequency of β(1)-,β(2)- adrenoceptor positive macrophages. However, only the MFI of β(1)-adrenoceptor and the frequency of β(1)-adrenoceptor positive macrophages were increased by atenolol. Furthermore, both propranolol and atenolol promoted LPS-mediated dopamine β-hydroxylase protein expression and increased noradrenaline production in rat alveolar macrophages. This was accompanied by increased LPS-mediated IL-6 and TNF-α production in cell supernatants of alveolar macrophages.
These findings demonstrate that propranolol or atenolol upregulates alveolar macrophage adrenergic system, and the response may be β(1)-adrenergic receptor subtype dependent.
先前的研究表明,巨噬细胞可合成并释放儿茶酚胺,以自分泌方式调节免疫反应。这些反应部分由巨噬细胞上表达的β-肾上腺素能受体介导。一些β-肾上腺素能受体拮抗剂常用于临床。在此,我们研究了长期给予β-肾上腺素能受体拮抗剂是否会上调肺泡巨噬细胞的肾上腺素能系统及其潜在机制。
通过灌胃给予大鼠普萘洛尔(30毫克/千克·天)或阿替洛尔(5毫克/千克·天),持续4周。然后分离肺泡巨噬细胞,通过流式细胞术分析检测β(1)或β(2)-肾上腺素能受体的表达。通过蛋白质免疫印迹法评估多巴胺β-羟化酶的表达,并在肺泡巨噬细胞暴露于100纳克/毫升脂多糖(LPS)2小时或24小时后,使用酶联免疫吸附测定法测量细胞上清液中去甲肾上腺素、白细胞介素-6和肿瘤坏死因子-α的浓度。
普萘洛尔增加了β(1)、β(2)-肾上腺素能受体的平均荧光强度(MFI)以及β(1)-、β(2)-肾上腺素能受体阳性巨噬细胞的频率。然而,阿替洛尔仅增加了β(1)-肾上腺素能受体的MFI和β(1)-肾上腺素能受体阳性巨噬细胞的频率。此外,普萘洛尔和阿替洛尔均促进LPS介导的多巴胺β-羟化酶蛋白表达,并增加大鼠肺泡巨噬细胞中去甲肾上腺素的产生。这伴随着肺泡巨噬细胞细胞上清液中LPS介导的白细胞介素-6和肿瘤坏死因子-α产生增加。
这些发现表明,普萘洛尔或阿替洛尔上调肺泡巨噬细胞肾上腺素能系统,且该反应可能依赖于β(1)-肾上腺素能受体亚型。